<?xml version="1.0" encoding="UTF-8"?>
<p>Another inflammatory cytokine involved in COVID-19 disease is TNF-Î±, which can be targeted by mAbs like adalimumab. Currently, there are several trials registered for assessment of adalimumab or biosimilar mAbs (Qletli) for their safety and efficacy in COVID-19 treatment in China (ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract infections and reactivation of hepatitis B infection are common and concerning side effects [
 <xref rid="B203-ijms-21-05559" ref-type="bibr">203</xref>].
</p>
